Drug Database
GR

grass pollen vaccine (DepiQuick)

✓ Approved

Laboratorios LETI · therapeutic agent

What is grass pollen vaccine?

grass pollen vaccine is a therapeutic agent developed by Laboratorios LETI. It is approved for therapeutic indications via injectable (others) or oral (po) or subcutaneous injection or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesDepiQuick
CompanyLaboratorios LETI
RouteInjectable (Others), Oral (PO), Subcutaneous Injection, Sublingual (SL)/Oral Transmucosal
StatusApproved
Sources: ClinicalTrials.gov, Laboratorios LETI

Therapeutic Indications

grass pollen vaccine is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved
Immune system disordersHypersensitivity✓ Approved
Immune system disordersSeasonal allergy✓ Approved

Related Research Articles

PubMedJournal of hazardous materials2026-07-25

Differences in allergenic and toxic risks from airborne seed hairs and atmospheric PM2.5: Pollen, bacteria, and chemical components.

Yang Guoqing G, Huo Yaoqiang Y, Liu Mingqi M, Liu Wei W et al.

Airborne seed hairs released by poplar (Populus spp.) and willow (Salix spp.) during the fruiting period serve as unique carriers of biological particles, transporting substantial quantities of pollen-related plant materials and bacteria. However, its quantitative contribution to human allergenic and toxic risks relative to atmospheric particulate matter during the same period remains unclear. This study collected airborne seed hairs and PM2.5 simultaneously from urban and suburban areas in Hohhot, China, during May 2-8, 2025. We conducted the first quantitative comparison of the allergenic risks induced by pollen and bacteria based on specific immunoglobulin E (sIgE), and evaluated the toxic equivalent quantity of full-volatile organic compounds (FVOCs) and non-carcinogenic risks of heavy metals in seed hairs and PM2.5. The pollen and bacterial loads per unit mass of airborne seed hairs are 13.1 ± 12.1 and 92.9 ± 55.2 times higher than concurrent PM2.5, resulting in corresponding sIgE levels in airborne seed hairs that are 14.9 ± 13.5 and 124.0 ± 39.0 times higher than those in PM2.5. Pollen dominates the total allergenic risk in both carriers, accounting for 99.08% in airborne seed hairs and 99.89% in PM2.5, while the Salicaceae and Fabaceae as key pollen, respectively. However, the toxicity of FVOCs (dominated by semi-volatile organic compounds) and heavy metals in PM2.5 exceed 43754.2 ± 41130.6 and 41.8 ± 19.6 times greater than airborne seed hairs. We emphasize that airborne seed hairs should be incorporated as an independent seasonal high-risk factor into air quality exposure assessment and public health management.

PMID 42497725
Read full article →
PubMedAquatic toxicology (Amsterdam, Netherlands)2026-07-25

α-Ketoglutarate attenuates ammonium chloride-induced ferroptosis by maintaining mitochondrial homeostasis in grass carp (Ctenopharyngodon idellus) hepatocytes.

Zhang Yuling Y, Jiang Chengchen C, Li Dapeng D, Tang Rong R

Ammonia nitrogen is a common pollutant in aquaculture water, which can induce oxidative stress and inhibit growth in fish. α-ketoglutarate (AKG) has been proven to play an important role in alleviating oxidative stress and maintaining mitochondrial homeostasis. To investigate the regulatory mechanism of α-ketoglutarate in ammonium chloride-induced hepatocyte ferroptosis, flow cytometry and Western blotting were performed with grass carp hepatocytes as the experimental model. The results showed that ammonium chloride exposure could significantly reduce the viability of grass carp L8824 hepatocytes, significantly increase the expression levels of lipid reactive oxygen species (LipROS) and ACSL4 protein, and simultaneously cause damage to the morphological structure and physiological function of mitochondria, thereby inducing lipid peroxidation. In addition, ammonium chloride could also disrupt the cellular iron ion transport system, leading to abnormal accumulation of intracellular iron ions and ultimately inducing hepatocyte ferroptosis. After AKG intervention, hepatocyte viability was significantly improved, the expression levels of LipROS was significantly decreased, and lipid peroxidation damage was effectively alleviated. Meanwhile, mitochondrial homeostasis was maintained but the expression levels of ferroptosis-related genes did not show a significant changes. In summary, AKG may alleviate ammonium chloride stress-mediated ferroptosis in grass carp L8824 hepatocytes by scavenging intracellular reactive oxygen species and repairing mitochondrial function. The results of this study provide a new idea for ammonia nitrogen pollution control and healthy fish culture in aquaculture.

PMID 42497826
Read full article →
PubMedJournal of the International AIDS Society2026-07-25

Behavioural and Structural Determinants of Mpox Vaccine Awareness and Uptake Among People With HIV in the Dominican Republic: A Cross-Sectional Study.

Paulino-Ramirez Robert R, Matias Wilfredo R WR, Chaumette Alexandre A, Lora-Rodríguez Hector H et al.

Mpox disproportionately affects people with HIV (PWH), yet little is known about mpox vaccine awareness and uptake in low- and middle-income countries. We evaluated mpox-related knowledge, attitudes and practices (KAP) among PWH in the Dominican Republic to identify determinants of vaccine awareness and uptake. We conducted a cross-sectional online survey of 98 PWH recruited through HIV clinics, community-based organizations and social networks (January-May 2025). The questionnaire assessed sociodemographic characteristics, mpox-related KAP, structural barriers and vaccination status. Univariable and multivariable logistic regression were used to examine factors associated with mpox vaccine awareness. Half of the participants (49/98) were aware of the mpox vaccine. Individuals aged 31-40 years had significantly lower odds of awareness compared with those aged 21-30 years. Despite high levels of formal education, 79% rated their mpox knowledge as low, and most perceived minimal personal risk. Among participants aware of the vaccine, 71% had been vaccinated. Structural barriers, including inconvenient site locations and logistical challenges, were frequently reported, even among vaccinated individuals, indicating that access limitations rather than hesitancy were the dominant constraints. Trust in vaccinating organizations was high overall, and healthcare providers and community organizations were the primary sources of vaccine information. Peer and community influence emerged as notable facilitators of uptake, while lack of reliable information and concerns about vaccine safety contributed to hesitancy. Mpox vaccine awareness among PWH in the Dominican Republic was low, but willingness to vaccinate was high when individuals were informed and able to access services. Strengthening mpox preparedness will require expanding accessible vaccination sites, improving disease-specific health literacy, and leveraging trusted community and clinical networks. Integrating mpox vaccination into routine HIV care delivery and enhancing community-led outreach may substantially improve uptake in this and similar low-middle income countries (LMIC) settings.

PMID 42499164
Read full article →
PubMedPneumonia (Nathan Qld.)2026-07-25

Pneumococcal pneumonia in adults - re-emergence of vaccine serotypes: a prospective multicenter cohort study in Germany, 2020-2023.

Bahrs Christina C, Rose Norman N, Barten-Neiner Grit G, Fleischmann-Struzek Carolin C et al.

The main burden of non-invasive pneumococcal diseases in adults is largely due to community-acquired pneumonia (CAP). This study aimed to investigate the distribution and dynamics of pneumococcal vaccine serotypes and to determine the proportion of CAP cases attributable to serotypes covered by 13-valent conjugate vaccine (PCV13), the 20-valent conjugate vaccine (PCV20), and the 23-valent polysaccharide vaccine (PPV23) among adults in Germany from 2020 to 2023. In this prospective multicenter cohort study, we analyzed all adult patients with CAP enrolled between January 1, 2020, and December 31, 2023, at 26 centers in Germany who provided urine samples for serotype-specific urine antigen detection (SSUAD) testing. Annual trends of pneumococcal vaccine serotypes from 2020 to 2023 were calculated for all patients and patient groups at risk using cluster-robust generalized linear models with heteroscedasticity-consistent standard errors. Of the 2,028 patients with all-cause CAP, 1,504 (1,008 patients aged ≥ 60 years, 373 younger patients with at least one comorbidity) had urine samples analyzed with SSUAD tests. Overall proportion of vaccine-type pneumococcal pneumonia among all-cause CAP for PCV13, PCV20, and PPV23 serotypes was 5.41% (95% CI 4.12-7.06%), 8.11% (95% CI 6.35-10.31%), and 8.31% (95% CI 6.27-10.93%), and serotype 3 was the most prevalent serotype (52 cases). Among patients aged ≥ 60 years, an increasing annual trend was observed for serotype 3 (OR 1.84, 95% CI 1.01-2.67), PCV13 (OR 1.89, 95% CI 0.89-2.89), PCV20 (OR 1.57, 95% CI 0.99-2.14), and PPV23 serotypes (OR 1.47, 1.04-1.91). The findings demonstrate that vaccine serotypes, particularly serotype 3, continued to circulate and reemerged among older adults with CAP in Germany.

PMID 42498972
Read full article →
PubMedHospital pharmacy2026-07-25

Distribution and Characteristics of Vaccine Adverse Events: Analysis of Over 2 Million Individual Case Safety Reports.

Castellana Eleonora E, Chiappetta Maria Rachele MR

To describe the distribution and characteristics of adverse events following immunization (AEFI) using a large US pharmacovigilance database. A retrospective descriptive analysis of Individual Case Safety Reports (ICSRs) from the FDA AEMS database (January 2017-March 2026) was conducted. Reports were analyzed by vaccine type, adverse event terms, demographics, reporting year, and reporter category. A total of 2 169 603 ICSRs were identified, with 44.0% classified as serious. COVID-19 vaccines accounted for 78.4% of reports, reflecting mass vaccination campaigns. The most frequently reported events were headache (12.8%), pyrexia (11.8%), and fatigue (11.1%), predominantly non-serious and consistent with known reactogenicity profiles. Reporting peaked in 2021 (48.8%). Females accounted for 60.6% of reports. Non-COVID vaccines contributed substantially fewer reports. Most vaccine-associated adverse events were mild and expected. Findings support a favorable benefit-risk profile and highlight the importance of continuous pharmacovigilance systems for vaccine safety monitoring.

PMID 42500260
Read full article →
PubMedPediatric research2026-07-25

Immunogenicity and safety of BNT162b2 vaccine in patients with juvenile immune mediated inflammatory disease.

Gadelha Carolina S E CSE, Terreri Maria Teresa MT, N Burian Ana Paula AP, da Fraga Aline C M ACM et al.

COVID-19 vaccines have significantly reduced mortality and are safe for healthy children; however, research in pediatric populations with juvenile immune-mediated inflammatory diseases (IMIDs) is limited. The Brazilian multicenter longitudinal SAFER-Study evaluates immunogenicity and safety of the BNT162b2/Pfizer vaccine in IMID patients. The juvenile cohort enrolled patients aged 12-17 years between August and December 2021 and compared them with adults under 40 years from the adult cohort. Safety was assessed by monitoring post-vaccination adverse events (AEs), immunogenicity was measured by IgG antibodies against the SARS-CoV-2 spike receptor-binding domain and seroconversion rates. A total of 123 participants were included: 86 adolescents and 37 adult controls. In adolescents, local AEs were most frequent; no serious or life-threatening AEs occurred. Significant increases in IgG-S levels were observed after the two doses in both cohorts (p < 0.001). Seroconversion after the second dose reached 97% overall and 100% after the third dose. In juvenile SLE and JIA patients, vaccination did not significantly affect disease activity. The BNT162b2 vaccine was safe and immunogenic in adolescents with IMIDs, including those with high immunosuppression and comorbidities, showing similar responses to adults. These findings support vaccination in this vulnerable population and contribute to evidence-based recommendations. BNT162b2 COVID-19 vaccine demonstrated a favorable safety profile and immunogenicity in adolescents with juvenile immune-mediated inflammatory diseases (IMID), with responses comparable to those observed in adults. Real life data on this population remain limited, and further evidence regarding vaccine safety and immunogenicity is needed. This study represents the first multicenter, longitudinal registry of Brazilian adolescents with IMID receiving BNT162b2. Comprehensive data on the safety and immunogenicity of BNT162b2 in highly immunosuppressed adolescents with IMID and comorbidities are crucial to guide clinical decision-making, mitigate vaccine hesitancy, and enhance vaccination coverage within this vulnerable population.

PMID 42498827
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about grass pollen vaccine